Company intelligence / Profile preview
Zedira
Darmstadt, Hesse, Germanyzedira.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Zedira’s lead candidate, ZED1227, is a first-in-class oral tissue transglutaminase inhibitor. It demonstrated proof-of-concept and a placebo-like safety profile in a Phase 2a study for celiac disease. The company has additional small-molecule inhibitors targeting various indications related to dysregulated transglutaminases
- Therapeutic areas
- PulmonologyGastroenterologyOncologyNephrologyCardiovascular
- Modalities
- Small moleculePeptidomimetic compoundRecombinant protein (for research reagents)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals (collaboration and licensing agreement for celiac disease therapy development)Dr. Falk Pharma
Beyond the preview
Go deeper on Zedira.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zedira.